Phase I Study to Evaluate the Safety and Efficacy of MF101 as Well as the Pharmacokinetics of Its Key Active Components

Inclusion Criteria: * Post-menopausal females, in good health and between 40 and 65 years of age. * Normal body mass index equal or greater than 18 but not greater than 36 * Postmenopausal as defined by 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels \> 30 mlU/ml or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy, or hysterectomy with FSH levels \> 30 mlU/ml. * Ability to comprehend and a willingness to sign an informed consent form. * Ability and willingness to understand and follow study procedures. * Clinical laboratory evaluations within the reference range for the testing laboratory, unless regarded not clinically significant by the Principle Investigator. * Must have had mammogram within the last 9 months. * Negative urine test for selected drugs of abuse at screening and after check-in at the study unit. * Negative hepatitis panel (including HBsAg and anti-HCV), and HIV antibody screens. * No chronic medications being taken. * Must have a primary care physician. Exclusion Criteria: * History or clinical manifestations of significant metabolic, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, hepatic, gall bladder, renal, urological, or psychiatric disorders. * Dyslipidemia * History of abnormal renal function, uncontrolled hypertension, or malignancies. * History of breast, uterine or ovarian cancer or melanoma. * History of brain aneurism or ischemic events. * Febrile disease * Autoimmune disorders such as lupus erythematosis, multiple sclerosis or rheumatoid arthritis. * Severe vasomotor symptoms defined as \> 7/day or \>50/week. * Abnormal mammogram or breast examination within the last 9 months suggestive of cancer. * Abnormal Pap smear or pelvic examination within the last 9 months suggestive of cancer. * Double-wall endometrial thickness that exceeds 5 mm measured on transvaginal ultrasound. * Unexplained abnormal uterine bleeding within six months of enrollment. * Pregnancy or lactating. * History of deep vein thrombosis or pulmonary embolism requiring anticoagulation. * History of hypersensitivity or allergies to any drug compound, including the constituents of MF101 unless approved by the Principle Investigator. * History or presence of a clinically significant abnormal ECG (QTcB \> 450msec at screening or variation in QTcB \> 30msec at screening). * Likely to need medication during the study including contraceptives. * History of alcoholism or drug addiction within 1 year prior to study entry (i.e., prior to check-in on Day-1). * Use of any tobacco products (including cigarette, pipe, cigar, chewing, nicotine patch, or nicotine gum) within 6 months prior to study entry. * Receipt of any investigational drug within 60 days prior to study entry. * Use of prescription medications known to possibly be effective for the treatment of hot flashes within three months of enrollment for oral or transdermal drugs, or within 6 months of enrollment for implanted or injected drugs. * Use of raloxifene, tamoxifen or aromatase inhibitors within three months of enrollment. * Use of any other prescription medication or any alcohol-containing products/medications within 14 days prior to study entry. * Use of over-the-counter, non-prescription preparations, within 7 days prior to study entry. * Use of any caffeine-containing products/medications within 72 hours prior to study entry. * Donation of blood within 6 weeks prior to study entry or of plasma within 2 weeks prior to screening. * Receipt of blood products within 2 months prior to study entry. * Any other condition or prior therapy which, in the opinion of the Investigator, would make the subject unsuitable for this study.